Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Monday, May 12th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, analysts expect Neumora Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Neumora Therapeutics Trading Up 0.6 %
NASDAQ:NMRA traded up $0.00 during midday trading on Friday, hitting $0.78. 878,672 shares of the stock were exchanged, compared to its average volume of 1,490,317. The business has a 50-day moving average price of $1.01 and a two-hundred day moving average price of $5.19. The company has a market capitalization of $125.55 million, a price-to-earnings ratio of -0.42 and a beta of 2.89. Neumora Therapeutics has a one year low of $0.62 and a one year high of $17.19.
Analyst Ratings Changes
NMRA has been the topic of several recent research reports. Royal Bank of Canada restated a "sector perform" rating and issued a $4.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. Guggenheim cut shares of Neumora Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, March 7th. William Blair lowered shares of Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday, March 10th. Needham & Company LLC reiterated a "buy" rating and issued a $5.00 target price on shares of Neumora Therapeutics in a research note on Thursday, April 10th. Finally, HC Wainwright dropped their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Neumora Therapeutics presently has an average rating of "Hold" and a consensus target price of $9.29.
Read Our Latest Research Report on NMRA
Neumora Therapeutics Company Profile
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Recommended Stories
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
